钠-葡萄糖协同转运蛋白2抑制剂治疗与常染色体显性多囊肾病患者肾功能纵向变化
该回顾性队列研究纳入348例起始SGLT2i的常染色体显性多囊肾病(ADPKD)退伍军人,评估eGFR斜率变化。起始后前3个月eGFR斜率陡增至-2.78 ml/min per 1.73 m2 per 90天,随后3-12个月稳定于-0.07。在合并2型糖尿病的ADPKD患者中,与DPP4i相比,SGLT2i与前3个月eGFR下降更快相关,但3-12个月斜率更稳定。
要点
- ADPKD患者起始SGLT2i后前3个月eGFR下降加速,随后3-12个月趋于稳定。
- 合并2型糖尿病的ADPKD患者中,SGLT2i较DPP4i长期eGFR下降更慢。
- 作者认为SGLT2i对合并症较多的老年ADPKD患者可能有益,但需进一步研究。
核心结论
- 在起始SGLT2i的老年轻度ADPKD且糖尿病和心血管疾病高发患者中,eGFR在前3个月下降后于剩余一年随访期内稳定。
- 与DPP4i相比,SGLT2i在合并2型糖尿病的ADPKD患者中与起始后3-12个月更慢的eGFR下降相关。
- 这些发现提示SGLT2i对合并症可能在肾功能下降中起更大作用的老年ADPKD个体可能有益,但需进一步研究。
研究设计与样本
- 退伍军人健康管理局内的一项回顾性队列研究,纳入2017年1月至2023年5月期间起始SGLT2i且带有ADPKD诊断代码的成人。
- 采用重复测量模型评估SGLT2i起始前后的eGFR斜率。
- 在合并2型糖尿病的ADPKD患者中,采用目标试验模拟比较SGLT2i与DPP4i对eGFR斜率的影响。
主要发现
- 348例起始SGLT2i的ADPKD患者中,93%为男性,平均±SD年龄为68±11岁,中位eGFR为53(四分位距:16–127)ml/min per 1.73 m2。
- 调整分析中,起始前eGFR斜率为−0.79(95%CI,−1.26至−0.33)ml/min per 1.73 m2 per 90天。
- 起始后前3个月eGFR斜率陡增至−2.78(−4.04至−1.53)ml/min per 1.73 m2,随后3-12个月稳定于−0.07(−0.72至0.58)ml/min per 1.73 m2。
- 目标试验模拟比较217例SGLT2i使用者与198例DPP4i使用者;调整分析中,起始后前3个月SGLT2i使用者eGFR下降较DPP4i使用者快−4.03(−6.45至−1.60)ml/min per 1.73 m2 per 90天。
- 在后续3-12个月,SGLT2i起始者斜率较DPP4i起始者更稳定,差异为1.29(0.16至2.41)ml/min per 1.73 m2 per 90天。
局限性
- 原文结论指出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use has not been extensively studied in autosomal dominant polycystic kidney disease (ADPKD). In veterans with ADPKD, kidney function declined at a greater rate during the first 3 months post-SGLT2i initiation but subsequently attenuated. In veterans with ADPKD, SGLT2i versus dipeptidyl peptidase-4 inhibitor use was associated with slower long-term kidney function decline. BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a pillar of kidney disease therapy, but their efficacy remains unknown in autosomal dominant polycystic kidney disease (ADPKD). We evaluated effects of SGLT2i on kidney function in ADPKD. METHODS: This retrospective cohort study within the Veterans Health Administration included adults with an ADPKD diagnosis code who initiated SGLT2i between January 2017 and May 2023. Repeated measures models were used to evaluate eGFR slope before and after SGLT2i initiation. Among patients with ADPKD and type 2 diabetes mellitus, a target trial emulation was used to compare the effects of SGLT2i versus dipeptidyl peptidase-4 inhibitor (DPP4i) on eGFR slope. RESULTS: Among 348 eligible patients with ADPKD who started an SGLT2i, 93% were male, mean±SD age was 68±11, and median eGFR was 53 (interquartile range: 16–127) ml/min per 1.73 m2. In adjusted analyses, the preinitiation eGFR slope was −0.79 (95% confidence interval, −1.26 to −0.33) ml/min per 1.73 m2 per 90 days. The eGFR slope steepened to −2.78 (−4.04 to −1.53) ml/min per 1.73 m2 during the first 3 months postinitiation and then stabilized to −0.07 (−0.72 to 0.58) ml/min per 1.73 m2 during months 3–12 postinitiation. The target trial emulation compared 217 SGLT2i users with 198 DPP4i users. In adjusted analyses, eGFR declined −4.03 (−6.45 to −1.60) ml/min per 1.73 m2 per 90 days faster in SGLT2i users versus DPP4i users during the first 3 months postinitiation; however, during the subsequent 3–12 months, the slope was more stable in SGLT2i initiators than DPP4i initiators, with a difference of 1.29 (0.16 to 2.41) ml/min per 1.73 m2 per 90 days. CONCLUSIONS: In older patients with mild ADPKD and a high prevalence of diabetes and cardiovascular disease who initiated an SGLT2i, there was an initial 3-month decline in eGFR followed by stabilization during the remainder of the year-long follow-up. Compared with DPP4i use, SGLT2i use was associated with a slower eGFR decline between 3 and 12 months postinitiation in patients with concurrent type 2 diabetes mellitus. These findings suggest that SGLT2is are potentially beneficial in older individuals with ADPKD in whom comorbid disease may play a greater role in kidney function decline, but further studies are required.
引用
- Eswarappa M, Madden E, Shlipak MG, et al. Sodium-Glucose Cotransporter-2 Inhibitor Therapy and Longitudinal Changes in Kidney Function among Veterans with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2025. PMID: 40377984. doi:10.2215/CJN.0000000725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。